Scroll to top

2021 Announcements

CLINUVEL
Posted by CLINUVEL
April 11, 2021

CLINUVEL Strategic Update II

Melbourne, Australia, 12 April 2021 CLINUVEL today announced its second Strategic Update,...

Read More
CLINUVEL.
Posted by CLINUVEL.
April 6, 2021

CLINUVEL Kommuniqué II

Liebe Aktionäre, Freunde Wir begrüßen viele neue Aktionäre, insbesondere die große Anzahl...

Read More
CLINUVEL
Posted by CLINUVEL
April 1, 2021

CLINUVEL Communiqué II

Dear shareholders, friends We welcome many new shareholders, especially the large number...

Read More
CLINUVEL
Posted by CLINUVEL
March 31, 2021

Chair's Letter I

Direction and horizon In the last weeks, I have had investor questions...

Read More
CLINUVEL
Posted by CLINUVEL
March 24, 2021

Media Release - CLINUVEL Expands DNA Repair Program

SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) CLINUVEL...

Read More
CLINUVEL
Posted by CLINUVEL
March 24, 2021

SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)

CLINUVEL today announced that it has reached agreement with clinical and academic...

Read More
CLINUVEL
Posted by CLINUVEL
March 10, 2021

Investor Presentation - Daiwa Investment Conference Tokyo 2021

10 March 2021 – Melbourne, Australia On 10 March 2021 CLINUVEL presented...

Read More
CLINUVEL
Posted by CLINUVEL
March 5, 2021

Appendix 3Y Change of Director's Interest Notice

CLINUVEL PHARMACEUTICALS LTD today released the attached Appendix 3Y which relates to...

Read More
CLINUVEL
Posted by CLINUVEL
March 3, 2021

Appendix 3Y Change of Director's Interest Notice

Information or documents not available now must be given to ASX as...

Read More
CLINUVEL
Posted by CLINUVEL
March 1, 2021

SCIENTIFIC COMMUNIQUÉ IX

Beyond Pigment, the Melanocortin 1 Receptor (MC1R) in DNA Repair March 2021...

Read More
CLINUVEL
Posted by CLINUVEL
February 24, 2021

Operations Update Webinar

https://vimeo.com/516430955/8f3e88ca5c

Read More
CLINUVEL
Posted by CLINUVEL
February 24, 2021

CLINUVEL Reports Tenth Consecutive Half Year Net Profit

KEY HIGHLIGHTS, HALF YEAR ENDED 31 DECEMBER 2020 Consolidated Entity Result Change...

Read More
CLINUVEL
Posted by CLINUVEL
February 24, 2021

Appendix 4D Half Year Report

Results For Announcement To The Market ($A’000) Revenues from continuing activities Increased...

Read More
Jenna Reid
Posted by Jenna Reid
February 19, 2021

Financial Results Half Year Ended 31 December 2020

Operations Update I Webinar CLINUVEL PHARMACEUTICALS LTD CLINUVEL PHARMACEUTICALS LTD will host...

Read More
CLINUVEL
Posted by CLINUVEL
February 11, 2021

SCENESSE® Granted Market Access In Israel

CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...

Read More
CLINUVEL
Posted by CLINUVEL
January 28, 2021

Kommuniqué I

Liebe Freunde, Aktionäre, Wir sind in ein neues Jahr eingetreten, eines voller...

Read More
We use cookies to give you the best experience.